Illumina (NASDAQ:ILMN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.450-4.55 for the period, compared to the consensus estimate of 4.227. The company issued revenue guidance of -.
Illumina Price Performance
NASDAQ ILMN traded down $3.95 on Thursday, hitting $102.71. 3,417,274 shares of the company's stock were exchanged, compared to its average volume of 2,396,635. The stock has a 50-day moving average of $93.07 and a 200-day moving average of $93.46. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. Illumina has a 52 week low of $68.70 and a 52 week high of $156.66. The stock has a market cap of $16.26 billion, a price-to-earnings ratio of -16.92, a P/E/G ratio of 2.12 and a beta of 1.36.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. Analysts expect that Illumina will post 4.51 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on ILMN shares. Guggenheim decreased their price objective on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. Piper Sandler decreased their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. Royal Bank Of Canada decreased their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday. Finally, Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective for the company. in a report on Friday, July 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $125.89.
Check Out Our Latest Stock Analysis on ILMN
Insider Activity at Illumina
In other news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.60% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Illumina
A hedge fund recently raised its stake in Illumina stock. Empowered Funds LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 113.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,284 shares of the life sciences company's stock after buying an additional 4,940 shares during the quarter. Empowered Funds LLC's holdings in Illumina were worth $737,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 89.42% of the company's stock.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
